Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZBX - Genzyme Biosurgery -- Ignore unavailable to you. Want to Upgrade?

To: Joan Osland Graffius who wrote (3)	2/11/2001 2:18:17 PM
From: Spekulatius	Read Replies (3) \| Respond to of 18

GZBX at 4$ would be a terrific price. The company would have a market cap of 150M$ with 250M$ in revenue.I do not think it will go that low but who knows. My major concern is that GZBX will be fairly low on cash at the end of this year according to the financial guidance they expet a total cash consumption of 75M$ for investment and working capital needs but have only 90M$ in cash. On the other hand,with drug like gross margins of 60% and a growth rate of 15-20%, they GZBX be able to be cash flow positive next year, if they keep a lid on R&D expenses.